Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2019 to Q4 2025

Type / Class
Equity / Common Stock, $0.001 par value per share
Symbol
TRVI on Nasdaq
Shares outstanding
128,120,714
Price per share
$10.51
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
130,299,550
Total reported value
$1,631,366,327
% of total 13F portfolios
0%
Share change
+566,328
Value change
+$9,406,834
Number of holders
182
Price from insider filings
$10.51
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
New Enterprise Associates 16, L.P. 12% -23% $170,186,363 15,074,080 0% New Enterprise Associates 16, L.P. 07 Aug 2025
Frazier Life Sciences Public Fund, L.P. 7% -33% $77,848,392 -$16,025,200 8,508,021 -17% Frazier Life Sciences Public Fund, L.P. 30 Sep 2025
BlackRock, Inc. 5.6% $62,259,693 6,804,338 BlackRock, Inc. 30 Sep 2025
FMR LLC 5.1% $81,380,117 6,500,009 FMR LLC 31 Dec 2025
VANGUARD GROUP INC 5% $80,561,881 6,434,655 The Vanguard Group 31 Dec 2025
VIKING GLOBAL INVESTORS LP 4.2% -28% $46,929,206 -$21,747,894 5,128,875 -32% VIKING GLOBAL INVESTORS LP 30 Sep 2025
Rubric Capital Management LP 2.9% -60% $42,526,596 -$53,798,103 3,766,749 -56% Rubric Capital Management LP 31 Dec 2025
Venrock Healthcare Capital Partners II, L.P. 1.4% $8,042,002 1,266,457 Venrock Healthcare Capital Partners II, L.P. 31 Dec 2024
Rosalind Advisors, Inc. 1.2% $6,746,875 1,062,500 Rosalind Advisors, Inc. 13 Feb 2025

As of 31 Dec 2025, 182 institutional investors reported holding 130,299,550 shares of Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI). This represents 102% of the company’s total 128,120,714 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI) together control 79% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
NEA Management Company, LLC 10% 13,222,228 0% 8.4% $165,542,295
Frazier Life Sciences Management, L.P. 8% 10,259,409 0% 3.4% $128,447,801
BlackRock, Inc. 7.9% 10,126,183 +2.3% 0% $126,779,812
FMR LLC 5.1% 6,500,009 +97% 0% $81,380,117
VANGUARD GROUP INC 5% 6,434,655 +10% 0% $80,561,880
Vivo Capital, LLC 4% 5,094,668 0% 4.1% $63,785,243
MARSHALL WACE, LLP 3.6% 4,580,548 -5.4% 0.06% $57,348,462
Rubric Capital Management LP 2.9% 3,766,749 -56% 0.56% $47,159,697
WELLINGTON MANAGEMENT GROUP LLP 2.7% 3,403,990 +4.6% 0.01% $42,617,956
MPM BIOIMPACT LLC 2.6% 3,287,087 -3.5% 4.7% $41,154,329
VIKING GLOBAL INVESTORS LP 2.5% 3,198,644 -38% 0.11% $40,047,023
ORBIMED ADVISORS LLC 2.5% 3,190,700 -3.6% 0.85% $39,947,564
ALLIANCEBERNSTEIN L.P. 2.4% 3,082,986 -28% 0.01% $38,598,985
Octagon Capital Advisors LP 2.2% 2,815,000 0% 4.4% $35,243,800
EVENTIDE ASSET MANAGEMENT, LLC 2% 2,622,306 +90% 0.51% $32,831,271
STATE STREET CORP 1.9% 2,435,000 +9.7% 0% $30,486,200
GEODE CAPITAL MANAGEMENT, LLC 1.9% 2,412,885 +8.6% 0% $30,214,388
Siren, L.L.C. 1.8% 2,286,867 -9.9% 0.85% $28,631,575
Affinity Asset Advisors, LLC 1.7% 2,150,172 -23% 1.9% $26,920,153
ACORN CAPITAL ADVISORS, LLC 1.7% 2,144,844 0% 9.1% $26,853,447
Artia Global Partners LP 1.6% 2,013,602 +0.7% 4.1% $25,210,297
EMERALD ADVISERS, LLC 1.5% 1,892,276 0.73% $23,691,296
RAYMOND JAMES FINANCIAL INC 1.4% 1,766,963 +25% 0.01% $22,122,376
Logos Global Management LP 1.2% 1,550,000 -30% 1.3% $19,406,000
Pictet Asset Management Holding SA 1.2% 1,532,013 +13507% 0.02% $19,180,803

Institutional Holders of Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 130,299,550 $1,631,366,327 +$9,406,834 $12.52 182
2025 Q3 129,323,951 $1,183,258,435 +$141,190,764 $9.15 163
2025 Q2 114,653,135 $627,154,153 +$139,569,505 $5.47 153
2025 Q1 88,130,237 $554,340,184 +$59,175,189 $6.29 137
2024 Q4 79,496,969 $329,526,035 +$80,359,022 $4.12 109
2024 Q3 58,119,888 $194,118,470 +$7,244,002 $3.34 92
2024 Q2 55,906,669 $166,602,895 +$12,771,260 $2.98 76
2024 Q1 51,561,502 $177,886,781 -$90,828 $3.45 79
2023 Q4 52,233,706 $69,993,370 -$4,018,362 $1.34 62
2023 Q3 48,682,678 $106,127,667 -$321,362 $2.18 55
2023 Q2 48,822,080 $116,683,910 +$12,840,858 $2.39 53
2023 Q1 43,462,507 $80,405,139 +$498,873 $1.85 35
2022 Q4 43,185,947 $83,348,629 -$3,845,159 $1.93 36
2022 Q3 45,770,959 $70,490,000 +$26,192,291 $1.54 37
2022 Q2 28,751,331 $80,790,000 +$28,742,730 $2.81 31
2022 Q1 7,161,506 $15,754,000 +$2,083,345 $2.20 20
2021 Q4 13,166,532 $10,286,000 -$218,769 $0.78 15
2021 Q3 12,448,249 $17,424,000 -$63,952 $1.40 15
2021 Q2 12,478,497 $28,076,000 -$1,746,455 $2.25 15
2021 Q1 13,128,768 $35,591,000 +$338,711 $2.71 17
2020 Q4 13,007,586 $31,748,000 -$644,938 $2.42 17
2020 Q3 13,263,517 $53,451,000 -$728,128 $4.03 13
2020 Q2 13,374,829 $88,003,000 -$1,315,702 $6.58 12
2020 Q1 13,964,620 $45,943,000 -$779,902 $3.29 17
2019 Q4 14,179,323 $53,174,000 -$140,814 $3.75 16
2019 Q3 14,115,568 $63,519,000 -$267,929 $4.50 17
2019 Q2 14,171,891 $106,290,000 +$106,290,000 $7.50 18